BCP-84 and BCP-85 showed higher tumor inhibition efficacy over either of anti-PD-L1 or anti-CTLA-4 monotherapy in C57BL/6CTLA-4 knock-in mice bearing a colorectal MC38 tumor. Here, CTLA4 is linked to neoplasm.